Pyrimidine JAK inhibitors for the treatment of skin diseases

A compound of formula (I):

• wherein R1 is F or H;
• L is selected from the group consisting of a bond, —CH2O—, —O—, and —OCH2—;
• R2 is selected from the group consisting of oxetane, tetrahydrofuran, tetrahydropyran, and oxepane;
• each of which is optionally substituted with 1 to 3 Ra;
• each Ra is independently selected from the group consisting of F, CN, OH, C1-4 alkyl-OH, C1-4 alkoxy, and C1-4 alkyl wherein the C1-4 alkyl is optionally substituted with 1 to 3 fluoro groups;
• R3 is selected from the group consisting of:
• (a) —S(O)2-C1-4alkyl, wherein C1-4alkyl is optionally substituted with CN or 1 to 3 fluoro groups;
• (b) —C1-4 alkyl-CONRxRy, wherein each of Rx and Ry is independently selected from H and C1-4 alkyl, wherein optionally Rx and Ry may be joined to form a 4 to 6 membered heterocyclic group;
• (c) —C(O)Rb, wherein Rb is C1-4alkyl optionally substituted with C3-6cycloalkyl, C1-4 alkoxy, or 1 to 3 fluoro groups;
• and
• (d) —CO2Rc wherein Rc is selected from
• (i) C1-4 alkyl optionally substituted with C1-4 alkoxy, and
• (ii) 4 to 7 membered heterocyclic group;
• or a pharmaceutically-acceptable salt thereof.